This Article Full Text Full Text (PDF) All Versions of this Article: 107/18/2307    most recent 01.CIR.0000066696.57519.AFv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, R. T. Articles by Sane, D. C. Search for Related Content PubMed PubMed Citation Articles by Williams, R. T. Articles by Sane, D. C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Heart Attack Hazardous Substances DB HEPARIN Related Collections Heparin Acute coronary syndromes Platelets Other Vascular biology

(Circulation. 2003;107:2307.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Anti-Platelet Factor 4/Heparin Antibodies

An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes

R. Taylor Williams, MD; Lakshmi V. Damaraju, PhD; Mary Ann Mascelli, PhD; Elliot S. Barnathan, MD; Robert M. Califf, MD; Maarten L. Simoons, MD; Efthymios N. Deliargyris, MD; David C. Sane, MD

From the Section of Cardiology (R.T.W., E.N.D., D.C.S.), Wake Forest University School of Medicine, Winston-Salem, NC; Centocor (L.V.D., M.A.M., E.S.B.), Malvern, Pa; Duke University Medical Center (R.M.C.), Durham NC; and Thoraxcenter University Hospital (M.L.S.), Rotterdam, the Netherlands.

Correspondence to David C. Sane, MD, Wake Forest University School of Medicine, Section of Cardiology, Medical Center Boulevard, Winston-Salem, NC 27157-1045. E-mail dsane{at}wfubmc.edu

Background— We postulated that antibodies to platelet factor 4/heparin complex might contribute to recurrent ischemic events in patients with acute coronary syndrome.

Methods and Results— We analyzed serum from patients enrolled in the placebo/unfractionated heparin arm of the GUSTO IV-ACS trial who had high likelihood of prior heparin exposure. We selected 109 patients without thrombocytopenia with the 30-day primary end point (death, myocardial infarction [MI], or revascularization) and 109 age-, gender-, and race-matched controls who did not achieve the primary end point. An ELISA for anti-platelet factor 4/heparin antibodies was performed using 48-hour serum samples. The analyses were done by blinded investigators, and the results were correlated with clinical outcomes. Twenty-three of 218 patients (10.6%) had anti-PF4/heparin antibodies. Patients with anti-PF4/heparin antibodies were more likely to have death or MI (30.4% versus 11.3%, P=0.011) or MI (21.7% versus 6.2%, P=0.008) than patients who were negative for the antibody. After multiple logistic regression analysis, anti-PF4/heparin antibodies remained a predictor of 30-day death or MI (odds ratio, 4.0; 95% CI, 1.4 to 11.3; P=0.0093) and MI (odds ratio, 4.6; 95% CI, 1.4 to 15.0; P=0.0108). The antibody was not associated with the composite end point (death, MI, or revascularization) or with death or revascularization alone.

Conclusions— Antibodies to the platelet factor 4/heparin complex are a novel, independent predictor of myocardial infarction at 30 days in patients presenting with acute coronary ischemic syndromes. This finding may explain the previous association between thrombocytopenia and adverse events in patients with acute coronary syndrome and may have important implications for the choice of anticoagulant regimens.

Key Words: heparin • thrombosis • antibodies • platelets

This article has been cited by other articles:

				A V Mattioli, L Bonetti, U Carletti, G Ambrosio, and G Mattioli Thrombotic events in patients with antiplatelet factor 4/heparin antibodies Heart, August 15, 2009; 95(16): 1350 - 1354. [Abstract] [Full Text] [PDF]

				A. O. Kanaan and A. S. Al-Homsi Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis, and Review of Pharmacotherapy Journal of Pharmacy Practice, April 1, 2009; 22(2): 149 - 157. [Abstract] [PDF]

				D. Paparella, G. Scrascia, A. Galeone, M. Coviello, G. Cappabianca, M. T. Venneri, B. Favoino, M. Quaranta, L. de Luca Tupputi Schinosa, and T. E. Warkentin Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1456 - 1463. [Abstract] [Full Text] [PDF]

				J. Fareed, R. L. Bick, G. Rao, S. Z. Goldhaber, A. Sasahara, H. L. Messmore, D. A. Happensteadt, and A. Nicolaides The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 5 - 7. [PDF]

				A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]

				D. C. Kress, S. Aronson, M. L. McDonald, M. I. Malik, A. B. Divgi, A. J. Tector, F. X. Downey III, A. J. Anderson, M. Stone, and C. Clancy Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes Ann. Thorac. Surg., May 1, 2007; 83(5): 1737 - 1743. [Abstract] [Full Text] [PDF]

				E. Bennett-Guerrero, T. F. Slaughter, W. D. White, I. J. Welsby, C. S. Greenberg, H. El-Moalem, and T. L. Ortel Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1567 - 1572. [Abstract] [Full Text] [PDF]

				D. M. Arnold and J. G. Kelton Heparin-Induced Thrombocytopenia: An Iceberg Rising Mayo Clin. Proc., August 1, 2005; 80(8): 988 - 990. [PDF]

				I.-K. Jang and M. J. Hursting When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia Circulation, May 24, 2005; 111(20): 2671 - 2683. [Full Text] [PDF]

				W. H. Matthai Jr Thrombocytopenia in Cardiovascular Patients: Diagnosis and Management Chest, February 1, 2005; 127(2_suppl): 46S - 52S. [Abstract] [Full Text] [PDF]

				P. Kumar, D. A. Hoppensteadt, M. M. Prechel, R. B. Deddish, and J. M. Walenga Prevalance of Heparin-Dependent Platelet-Activating Antibodies in Preterm Newborns After Exposure to Unfractionated Heparin Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 335 - 339. [Abstract] [PDF]

				A. Koster and T. Fischer Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416. [Abstract] [PDF]